Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 2/20 | 0.38 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570535 | 0.86 | HPGD (0.46) | MAPTLMNAALDH1A1 | |
| SCHEMBL28845910 | 0.79 | RXFP1 (0.44) | RXFP1MAPTPOLBLMNAMAPK1 | |
| SCHEMBL20569194 | 0.76 | PSMB8 (0.36) | POLBPDE4BSMN1; SMN2 | |
| SCHEMBL22184129 | 0.74 | MTNR1A (0.50) | POLB | |
| SCHEMBL22184236 | 0.73 | SLC6A2 (0.32) | — | |
| SCHEMBL22184132 | 0.73 | MTNR1A (0.44) | POLB | |
| SCHEMBL22184085 | 0.72 | POLB (0.41) | POLBLMNAALDH1A1 | |
| SCHEMBL1206771 | 0.71 | LTB4R (0.56) | RXFP1MAPTLMNAPPARA | |
| SCHEMBL22184151 | 0.71 | MTNR1A (0.42) | — | |
| SCHEMBL1667510 | 0.70 | HDAC3 (0.44) | RXFP1MAPTLMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-15 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223319-A2 | METHOD AND MOLECULES | MedImmune, LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3630732-B1 | METHOD AND MOLECULES | MEDIMMUNE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-110650947-B | Methods and molecules | 免疫医疗有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
| US-20200206359-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-02 | — | — | US | disclosed |
| EP-3630732-A1 | METHOD AND MOLECULES | Medimmune, LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110650947-A | Methods and molecules | 免疫医疗有限责任公司 | 2020-01-03 | — | — | CN | disclosed |
| WO-2018218093-A1 | METHOD AND MOLECULES | MEDIMMUNE, LLC (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152728-A1 | Method And Molecules | PAICS, EPCAM, SQLE | RXFP1 2669/4885MAPT 3818/4885POLB 4453/4885 |
| US-20200206359-A1 | Method And Molecules | PAICS, EPCAM, SQLE | RXFP1 2669/4885MAPT 3818/4885POLB 4453/4885 |
| US-20230321267-A1 | Method And Molecules | PAICS, EPCAM, SQLE | RXFP1 2669/4885MAPT 3818/4885POLB 4453/4885 |
| US-11759526-B2 | Method and molecules | PAICS, EPCAM, SQLE | RXFP1 2669/4885MAPT 3818/4885POLB 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.